In-situ radioactive medical device

• US 6,264,596 B1
• Filed: 11/03/1997
• Issued: 07/24/2001
• Est. Priority Date: 11/03/1997
• Status: Expired due to Fees

• Current Assignee: Boston Scientific Scimed (Boston Scientific Corporation)
• Original Assignee: Meadox Medicals, Inc. (Boston Scientific Corporation)
• Inventors: Weadock, Kevin S.
• Primary Examiner(s): Lacyk, John P.
• Application Number:
  US08/962,749
• Time in Patent Office: 1,359 Days
• Field of Search: 600/1-8
• US Class Current: 600/3
• CPC Class Codes: A61K 51/0495 Pretargeting

Abstract

Devices and methods for rendering an intravascular stent radioactive in-situ, after stent placement. A stent is provided having a tubular body and a first substance immobilized on body. The first substance preferably has a high and selective affinity for a second substance which can be radioactive, cytotoxic or thrombolytic. The first substance can also have an affinity for growth factors or thrombolytic, chemolytic or cytotoxic agents. The stent can be placed across a stenosed blood vessel region, preferably after dilation by angioplasty or atherectomy. After stent placement within the vessel, the second substance can be injected into the blood stream of a patient. With each pass through the stent, the second substance is increasingly bound to the first substance on the stent. Suitable complementary substance pairs include avidin and radio-labeled biotin, protamine and radioactive heparin, and protein and anti-protein antibody.

Claims

1. A medical device adapted for placement at an intravascular treatment site to inhibit restenosis, the device comprising:

a device surface;

a first substance immobilized on said device surface; and

a radioactive second substance suitable for intravascular injection, wherein said first substance is adapted to bind said radioactive second substance when said second substance is intravascularly injected.

2. A medical device as recited in claim 1, wherein said binding is strong and selective between said first and second substance.

3. A medical device as recited in claim 2, wherein said binding has a dissociation constant of less than about 10⁻

12 M.

4. A medical device as recited in claim 3, wherein said binding has a dissociation constant of less than about 10⁻

14 M.

5. A medical device as recited in claim 4, wherein said binding has a dissociation constant of less than about 10⁻

15 M.

6. A medical device as recited in claim 2, wherein said first substance is a ligand and said second substance is an anti-ligand.

7. A medical device as recited in claim 1, wherein said first substance is selected from the group consisting of avidin, streptavidin, and proteins and said second substance is selected from the group consisting of radio-labeled biotin, radio-labeled monoclonal antibodies, and radio-labeled polyclonal antibodies.

8. A medical device as recited in claim 7, wherein said first substance is avidin and said second substance is radio-labeled biotin.

9. A medical device as recited in claim 7, wherein said first substance is protamine and said second substance is radio-labeled heparin.

10. A medical device as recited in claim 7, wherein said first substance is a protein and said second substance is radio-labeled antibody having an affinity for said protein.

11. A medical device as recited in claim 1, wherein said first substance is biotin and said second substance is radio-labeled avidin.

12. A medical device as recited in claim 1, wherein said first substance is biotin and said second substance is radio-labeled streptavidin.

38. A medical device as in claim 1, 13, 21, or 28, wherein the device comprises a tubular body.

39. A medical device as in claim 1, 13, 21, or 28, wherein the device comprises an implantable device.

40. A medical device as in claim 39, wherein the implantable device comprises a stent.

41. A medical device as in claim 1, 13, 21, or 28, wherein the first substance is adapted to bind to a third non-radioactive agent.

42. A medical device as in claim 41, wherein the third agent is a restenosis inhibiting agent.

43. A medical device as in claim 41, wherein the third agent is a growth factor.

44. A medical device as in claim 41, wherein the third agent is a thrombolytic agent.

45. A medical device as in claim 41, wherein the third agent is an anti-thrombogenic agent.

13. A medical device adapted for placement at an intravascular treatment site to inhibit restenosis, the device comprising:

a device surface;

a first substance immobilized on said device surface; and

a radioactive second substance suitable for intravascular injection, wherein said first substance is adapted to bind said radioactive second substance when said second substance is intravascularly injected, said second substance being selectively and strongly bound to said first substance.

14. A medical device as recited in claim 13, wherein said binding is selective and strong between said first and second substance.

15. A medical device as recited in claim 13, wherein said first substance is a ligand and said second substance is an anti-ligand.

16. A medical device as recited in claim 13, wherein said first substance is selected from the group consisting of avidin, streptavidin, and proteins and said second substance is selected from the group consisting of radio-labeled biotin, radio-labeled monoclonal antibodies, and radio-labeled polyclonal antibodies.

17. A medical device as recited in claim 16, wherein said first substance is avidin and said second substance is radio-labeled biotin.

18. A medical device as recited in claim 16, wherein said first substance is biotin and said second substance is selected from the group consisting of radio-labeled avidin and radio-labeled strepavidin.

19. A medical device as recited in claim 16, wherein said first substance is protamine and said second substance is radio-labeled heparin.

20. A medical device as recited in claim 16, wherein said first substance is a protein and said second substance is radio-labeled antibody having an affinity for said protein.

21. A kit for inhibiting restenois in blood vessels comprising:

a stent including

a tubular body, and

a first substance immobilized on said tubular body; and

a second substance adapted to bind to said first substance when said second substance is intravascularly injected, said second substance being radioactive, said substance being suitable for injection into the human blood stream.

22. A kit as recited in claim 21, wherein said first substance is a ligand and said second substance is an anti-ligand.

23. A kit as recited in claim 21, wherein said first substance is selected from the group consisting of avidin, streptavidin, and proteins and said second substance is selected from the group consisting of radio-labeled biotin, radio-labeled monoclonal antibodies, and radio-labeled polyclonal antibodies.

24. A kit as recited in claim 23, wherein said first substance is avidin and said second substance is radio-labeled biotin.

25. A kit as recited in claim 23, wherein said first substance is biotin and said second substance is selected from the group consisting of radio-labeled avidin and radio-labeled strepavidin.

26. A kit as recited in claim 24, wherein said first substance is protamine and said second substance is radio-labeled heparin.

27. A kit as recited in claim 23, wherein said first substance is a protein and said second substance is radio-labeled antibody having an affinity for said protein.

28. A system for inhibiting restenosis in blood vessels comprising:

a radioactive substance suitable for injection into the human blood stream; and

a stent including

a tubular body, and

means for binding said radioactive substance when said radioactive substance is intravascularly injected, said binding means being immobilized on said tubular body.

29. A method for inhibiting restenosis in a stenosed blood vessel region of a patient comprising the steps:

providing a radioactive substance suitable for injection into the human blood stream;

providing a medical device having a surface and means for binding said radioactive substance, said binding means connected to said surface;

placing said device across said stenosed region;

injecting said radioactive substance into the blood stream, such that said radioactive substance is bound to said binding means.

30. A method for inhibiting restenosis as recited in claim 29, wherein said means for binding includes avidin and said radioactive substance includes radio-labeled biotin.

31. A method for inhibiting restenosis as recited in claim 29, wherein said means for binding includes protamine and said radioactive substance includes radio-labeled heparin.

32. A method for inhibiting restenosis in a stenosed blood vessel region of a patient comprising the steps:

providing a medical device having a surface and a first substance immobilized on said surface;

providing a second substance suitable for injection into the human blood stream, said second substance being radioactive;

placing said medical device at said stenosed region;

injecting said second substance into the blood stream, such that said second substance is substantially bound to said first substance.

33. A method for inhibiting restenosis as recited in claim 32, wherein said first substance includes avidin and said second substance includes radio-labeled biotin.

34. A method for inhibiting restenosis as recited in claim 32, wherein said first substance includes biotin and said second substance is selected from the group consisting of radio-labeled avidin and radio-labeled streptavidin.

35. A method for inhibiting restenosis as recited in claim 32, wherein said first substance includes protamine and said second substance includes radio-labeled heparin.

46. A method for inhibiting restenosis as in claim 32, further comprising the steps of:

providing a third substance suitable for injection into the human blood stream, said third substance being non-radioactive and adapted to bind to said first substance;

injecting said third substance into the blood stream such that said third substance is substantially bound to said first substance.

36. A medical device adapted for intravascular placement comprising:

a device surface;

a first substance immobilized on said surface; and

a second substance suitable for intravascular injection, wherein said first substance is adapted to bind said second substance strongly and selectively when said second substance is intravascularly injected, and wherein said second substance is selected from the group consisting of cytotoxic substances, growth factors, thrombolytic agents and anti-thrombogenic agents.

37. A method for inhibiting restenosis in a stenosed blood vessel region of a patient comprising the steps:

providing a medical device having a surface and a first substance immobilized on said surface;

providing a second substance suitable for injection into the human blood stream, wherein said second substance is selected from the group consisting of cytotoxic substances, growth factors, thrombolytic agents and anti-thrombogenic agents;

placing said medical device at said stenosed region; and

injecting said second substance into said blood stream, such that said second substance is bound to said first substance.

47. A method for inhibiting restenosis as in claim 37, further comprising the steps of:

providing a third substance suitable for injection into the human blood stream, said third substance being radioactive and adapted to bind to said first substance;

injecting said third substance into the blood stream such that said third substance is substantially bound to said first substance.